The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Porembskaya O.Ya.
Federal state budgetary institution «Research Institute of Experimental Medicine», North-West Division of Russian Academy of Medical Sciences, St. Petersburg
Kosenko I.M.
Department of Pharmacology with the course of clinical pharmacology and pharmacoeconomics, Sankt-Peterburg State Pediatric Medical University, Sankt-Peterburg, Russia
Pharmacotherapy of Chronic Venous Disease – how to choose Appropriate Venoactive Drug?
Journal: Journal of Venous Disorders. 2018;12(3): 123‑133
Views: 4715
Downloaded: 124
To cite this article:
Porembskaya OYa, Kosenko IM. Pharmacotherapy of Chronic Venous Disease – how to choose Appropriate Venoactive Drug?. Journal of Venous Disorders.
2018;12(3):123‑133. (In Russ.)
https://doi.org/10.17116/flebo2018123123
Chronic venous disease (CVD) is a multicomponent process that develops with time as a consequence of hemodynamic changes of macro- and microcirculation. The shear stress shift leads to leukocytes and macrophages activation and proinflammatory mediators (including ICAM-1, VEGF, MMP) secretion and smooth muscle cells switching to the secretory type. The cascade of the inflammatory reactions causes venous wall remodeling, increasing the wall permeability and protein and fluid extravasation. Proinflammatory mediators activate nociceptors between endothelial and muscle cells. All those processes result in venous symptoms developing such as venous pain, oedema, legs heaviness and others well-known symptoms. Contemporary conceptions of chronic venous disease progression pathophysiological mechanisms allow us to determine possible effective therapeutic targets to reduce the degree of symptoms and signs manifestation. Venoactive drugs that nowadays are widely spread on the pharmaceutical market demonstrate varied effectiveness against different symptoms. Results of multipal investigations including metanalyses help us to define grades of recommendations for every venoactive drug and to individualize the treatment of patients according to the types of symptoms. Modern modifications of topical drugs with the help of adding essential phospholipids acting like transdermal delivery system enhance the effectiveness and help to reduce the severity of clinical manifistations of CVD especially in combination with venoactive drugs.
Authors:
Porembskaya O.Ya.
Federal state budgetary institution «Research Institute of Experimental Medicine», North-West Division of Russian Academy of Medical Sciences, St. Petersburg
Kosenko I.M.
Department of Pharmacology with the course of clinical pharmacology and pharmacoeconomics, Sankt-Peterburg State Pediatric Medical University, Sankt-Peterburg, Russia
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.